Cargando…
Proof of concept in utilizing in-trans surface display system of Lactobacillus plantarum as mucosal tuberculosis vaccine via oral administration in mice
BACKGROUND: Tuberculosis is one of the most common and deadliest infectious diseases worldwide affecting almost a third of the world’s population. Although this disease is being prevented and controlled by the Bacille Calmette Guérin (BCG) vaccine, the protective efficacy is highly variable and subs...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182793/ https://www.ncbi.nlm.nih.gov/pubmed/30309359 http://dx.doi.org/10.1186/s12896-018-0461-y |
_version_ | 1783362646706225152 |
---|---|
author | Mustafa, Anhar Danial Kalyanasundram, Jeevanathan Sabidi, Sarah Song, Adelene Ai-Lian Abdullah, Maha Abdul Rahim, Raha Yusoff, Khatijah |
author_facet | Mustafa, Anhar Danial Kalyanasundram, Jeevanathan Sabidi, Sarah Song, Adelene Ai-Lian Abdullah, Maha Abdul Rahim, Raha Yusoff, Khatijah |
author_sort | Mustafa, Anhar Danial |
collection | PubMed |
description | BACKGROUND: Tuberculosis is one of the most common and deadliest infectious diseases worldwide affecting almost a third of the world’s population. Although this disease is being prevented and controlled by the Bacille Calmette Guérin (BCG) vaccine, the protective efficacy is highly variable and substandard (0–80%) in adults. Therefore, novel and effective tuberculosis vaccine that can overcome the limitations from BCG vaccine need to be developed. RESULTS: A novel approach of utilizing an in-trans protein surface display system of Lactobacillus plantarum carrying and displaying combination of Mycobacterium tuberculosis subunit epitope antigens (Ag85B, CFP-10, ESAT-6, Rv0475 and Rv2031c) fused with LysM anchor motif designated as ACERL was constructed, cloned and expressed in Esherichia coli Rossetta expression host. Subsequently the binding capability of ACERL to the cell wall of L. plantarum was examined via the immunofluorescence microscopy and whole cell ELISA where successful attachment and consistent stability of cell wall binding up to 4 days was determined. The immunization of the developed vaccine of L. plantarum surface displaying ACERL (Lp ACERL) via the oral route was studied in mice for its immunogenicity effects. Lp ACERL immunization was able to invoke significant immune responses that favor the Th1 type cytokine response of IFN-γ, IL-12 and IL-2 as indicated by the outcome from the cytokine profiling of spleen, lung, gastrointestinal tract (GIT), and the re-stimulation of the splenocytes from the immunized mice. Co-administration of an adjuvant consisting of Lactococcus lactis secreting mouse IL-12 (LcIL-12) with Lp ACERL was also investigated. It was shown that the addition of LcIL-12 was able to further generate significant Th1 type cytokines immune responses, similar or better than that of Lp ACERL alone which can be observed from the cytokine profiling of the immunized mice’s spleen, lung and GIT. CONCLUSIONS: This study represents a proof of concept in the development of L. plantarum as a carrier for a non-genetically modified organism (GMO) tuberculosis vaccine, which may be the strategy in the future for tuberculosis vaccine development. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12896-018-0461-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6182793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61827932018-10-18 Proof of concept in utilizing in-trans surface display system of Lactobacillus plantarum as mucosal tuberculosis vaccine via oral administration in mice Mustafa, Anhar Danial Kalyanasundram, Jeevanathan Sabidi, Sarah Song, Adelene Ai-Lian Abdullah, Maha Abdul Rahim, Raha Yusoff, Khatijah BMC Biotechnol Research Article BACKGROUND: Tuberculosis is one of the most common and deadliest infectious diseases worldwide affecting almost a third of the world’s population. Although this disease is being prevented and controlled by the Bacille Calmette Guérin (BCG) vaccine, the protective efficacy is highly variable and substandard (0–80%) in adults. Therefore, novel and effective tuberculosis vaccine that can overcome the limitations from BCG vaccine need to be developed. RESULTS: A novel approach of utilizing an in-trans protein surface display system of Lactobacillus plantarum carrying and displaying combination of Mycobacterium tuberculosis subunit epitope antigens (Ag85B, CFP-10, ESAT-6, Rv0475 and Rv2031c) fused with LysM anchor motif designated as ACERL was constructed, cloned and expressed in Esherichia coli Rossetta expression host. Subsequently the binding capability of ACERL to the cell wall of L. plantarum was examined via the immunofluorescence microscopy and whole cell ELISA where successful attachment and consistent stability of cell wall binding up to 4 days was determined. The immunization of the developed vaccine of L. plantarum surface displaying ACERL (Lp ACERL) via the oral route was studied in mice for its immunogenicity effects. Lp ACERL immunization was able to invoke significant immune responses that favor the Th1 type cytokine response of IFN-γ, IL-12 and IL-2 as indicated by the outcome from the cytokine profiling of spleen, lung, gastrointestinal tract (GIT), and the re-stimulation of the splenocytes from the immunized mice. Co-administration of an adjuvant consisting of Lactococcus lactis secreting mouse IL-12 (LcIL-12) with Lp ACERL was also investigated. It was shown that the addition of LcIL-12 was able to further generate significant Th1 type cytokines immune responses, similar or better than that of Lp ACERL alone which can be observed from the cytokine profiling of the immunized mice’s spleen, lung and GIT. CONCLUSIONS: This study represents a proof of concept in the development of L. plantarum as a carrier for a non-genetically modified organism (GMO) tuberculosis vaccine, which may be the strategy in the future for tuberculosis vaccine development. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12896-018-0461-y) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-11 /pmc/articles/PMC6182793/ /pubmed/30309359 http://dx.doi.org/10.1186/s12896-018-0461-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Mustafa, Anhar Danial Kalyanasundram, Jeevanathan Sabidi, Sarah Song, Adelene Ai-Lian Abdullah, Maha Abdul Rahim, Raha Yusoff, Khatijah Proof of concept in utilizing in-trans surface display system of Lactobacillus plantarum as mucosal tuberculosis vaccine via oral administration in mice |
title | Proof of concept in utilizing in-trans surface display system of Lactobacillus plantarum as mucosal tuberculosis vaccine via oral administration in mice |
title_full | Proof of concept in utilizing in-trans surface display system of Lactobacillus plantarum as mucosal tuberculosis vaccine via oral administration in mice |
title_fullStr | Proof of concept in utilizing in-trans surface display system of Lactobacillus plantarum as mucosal tuberculosis vaccine via oral administration in mice |
title_full_unstemmed | Proof of concept in utilizing in-trans surface display system of Lactobacillus plantarum as mucosal tuberculosis vaccine via oral administration in mice |
title_short | Proof of concept in utilizing in-trans surface display system of Lactobacillus plantarum as mucosal tuberculosis vaccine via oral administration in mice |
title_sort | proof of concept in utilizing in-trans surface display system of lactobacillus plantarum as mucosal tuberculosis vaccine via oral administration in mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182793/ https://www.ncbi.nlm.nih.gov/pubmed/30309359 http://dx.doi.org/10.1186/s12896-018-0461-y |
work_keys_str_mv | AT mustafaanhardanial proofofconceptinutilizingintranssurfacedisplaysystemoflactobacillusplantarumasmucosaltuberculosisvaccineviaoraladministrationinmice AT kalyanasundramjeevanathan proofofconceptinutilizingintranssurfacedisplaysystemoflactobacillusplantarumasmucosaltuberculosisvaccineviaoraladministrationinmice AT sabidisarah proofofconceptinutilizingintranssurfacedisplaysystemoflactobacillusplantarumasmucosaltuberculosisvaccineviaoraladministrationinmice AT songadeleneailian proofofconceptinutilizingintranssurfacedisplaysystemoflactobacillusplantarumasmucosaltuberculosisvaccineviaoraladministrationinmice AT abdullahmaha proofofconceptinutilizingintranssurfacedisplaysystemoflactobacillusplantarumasmucosaltuberculosisvaccineviaoraladministrationinmice AT abdulrahimraha proofofconceptinutilizingintranssurfacedisplaysystemoflactobacillusplantarumasmucosaltuberculosisvaccineviaoraladministrationinmice AT yusoffkhatijah proofofconceptinutilizingintranssurfacedisplaysystemoflactobacillusplantarumasmucosaltuberculosisvaccineviaoraladministrationinmice |